Intellia Therapeutics (NTLA) Accumulated Depreciation (2015 - 2025)

Intellia Therapeutics (NTLA) has reported Accumulated Depreciation for 11 consecutive years, with $58.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Accumulated Depreciation rose 17.94% year-over-year to $58.6 million; the TTM figure through Dec 2025 stood at $58.6 million (up 17.94% YoY), while the FY2025 annual figure was $58.6 million, up 17.94% from the prior year.
• Accumulated Depreciation climbed to $58.6 million in Q4 2025 per NTLA's latest filing, from $49.7 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $58.6 million in Q4 2025 and bottomed at $26.1 million in Q4 2021.
• Historically, Accumulated Depreciation has averaged $41.5 million across 5 years, with a median of $39.9 million in 2023.
• Annual changes were most pronounced in 2021 — Accumulated Depreciation jumped 35.09% — and 2025, when it rose 17.94%.
• Intellia Therapeutics' Accumulated Depreciation stood at $26.1 million in 2021, then climbed by 27.13% to $33.2 million in 2022, then climbed by 20.07% to $39.9 million in 2023, then climbed by 24.66% to $49.7 million in 2024, then grew by 17.94% to $58.6 million in 2025.
• Business Quant data shows NTLA's Accumulated Depreciation at $58.6 million in Q4 2025, $49.7 million in Q4 2024, and $39.9 million in Q4 2023.